BOSTON, Aug. 09, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, provided a business and financial update for the second quarter 2023. Recent Business Highlights…Read More
Cue Biopharma Inc Cue Biopharma Reports Second Quarter 2023 Financial Results and Recent Business Highlights
